GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adimmune Corp (TPE:4142) » Definitions » EV-to-EBITDA

Adimmune (TPE:4142) EV-to-EBITDA : -59.56 (As of May. 31, 2025)


View and export this data going back to 2010. Start your Free Trial

What is Adimmune EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Adimmune's enterprise value is NT$8,746 Mil. Adimmune's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was NT$-147 Mil. Therefore, Adimmune's EV-to-EBITDA for today is -59.56.

The historical rank and industry rank for Adimmune's EV-to-EBITDA or its related term are showing as below:

TPE:4142' s EV-to-EBITDA Range Over the Past 10 Years
Min: -667.18   Med: -16.68   Max: 195.11
Current: -59.57

During the past 13 years, the highest EV-to-EBITDA of Adimmune was 195.11. The lowest was -667.18. And the median was -16.68.

TPE:4142's EV-to-EBITDA is ranked worse than
100% of 497 companies
in the Biotechnology industry
Industry Median: 8.25 vs TPE:4142: -59.57

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-31), Adimmune's stock price is NT$18.70. Adimmune's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was NT$-0.680. Therefore, Adimmune's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Adimmune EV-to-EBITDA Historical Data

The historical data trend for Adimmune's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adimmune EV-to-EBITDA Chart

Adimmune Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.72 70.19 33.59 -29.14 -105.88

Adimmune Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -26.61 -26.67 -26.75 -105.88 -63.58

Competitive Comparison of Adimmune's EV-to-EBITDA

For the Biotechnology subindustry, Adimmune's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adimmune's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adimmune's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Adimmune's EV-to-EBITDA falls into.


;
;

Adimmune EV-to-EBITDA Calculation

Adimmune's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=8745.655/-146.837
=-59.56

Adimmune's current Enterprise Value is NT$8,746 Mil.
Adimmune's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-147 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adimmune  (TPE:4142) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Adimmune's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=18.70/-0.680
=At Loss

Adimmune's share price for today is NT$18.70.
Adimmune's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.680.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Adimmune EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Adimmune's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Adimmune Business Description

Traded in Other Exchanges
N/A
Address
Tanxing Road, No. 3, Section 1, Tanzi District, Taichung, TWN, 427003
Adimmune Corp is a Taiwan-based company. It is engaged in the development, manufacture, and distribution of vaccines and other biological products. Its pipeline consists of products like AdimFlu-S (QIS) which is a vaccine intended for use in the prevention of influenza, and TetraFlu among others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from the USA, China, and other regions.

Adimmune Headlines

No Headlines